FDA inspection
Boehringer Ingelheim Biopharmaceuticals (China) Ltd.: FDA inspection ending Jun 9, 2023
FDA inspection 1218076 · Voluntary Action Indicated (VAI) · Shanghai
Key facts
| Inspection ID | 1218076 |
|---|---|
| Firm | Boehringer Ingelheim Biopharmaceuticals (China) Ltd. |
| FEI number | 3015009021 |
| Address | 1090 Halei Road, Trade Zone |
| City | Shanghai |
| Fiscal year | 2023 |
| Inspection end date | Jun 9, 2023 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | New Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data